Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Asif Merchant

Geriatric Medicine Chelmsford, MA Medical Doctor

NPI 1538152335 CMS profile 24505

290 Littleton Rd Unit 3, Chelmsford, MA 01824

Open in the dashboard

General payments

$6,125

23 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Asif Merchant of Chelmsford, MA is reported in the CMS Open Payments database as having received $6,125 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2023 General $59 1
2019 General $6,038 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Asif Merchant
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Asif Merchant were reported at $28. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.

Show as a table
Year Asif Merchant Geriatric Medicine median Middle half National median
2019 $6,038 $122 $40–$435 $163
2020 $0 $98 $25–$349 $114
2021 $0 $125 $34–$441 $132
2022 $0 $124 $36–$408 $149
2023 $59 $121 $41–$383 $160
2024 $0 $134 $41–$435 $164
2025 $28 $123 $35–$408 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $5,781 15 payments
  2. Janssen Pharmaceuticals, Inc $239 5 payments
  3. Neurocrine Biosciences, Inc. $59 1 payment
  4. Otsuka America Pharmaceutical, Inc. $28 1 payment
  5. Sunovion Pharmaceuticals Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $2,500 1 payment
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,625 2 payments
  3. Travel and Lodging $1,142 5 payments
  4. Food and Beverage $858 15 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $5,364 14 payments
  2. XARELTO $239 5 payments
  3. INGREZZA $59 1 payment
  4. REXULTI $28 1 payment
  5. INVOKANA $21 3 payments
  6. APTIOM $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 335 drugs

Part D claims

67,227

Median for Internal Medicine: 777

Drug cost

$2,531,244

Median for Internal Medicine: $73,373

Branded share of claims

17.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 2,869 $611,350
Nuplazid Pimavanserin Tartrate Brand 66 $115,375
Xifaxan Rifaximin Brand 95 $111,570
Jardiance Empagliflozin Brand 337 $68,014
Januvia Sitagliptin Phosphate Brand 333 $66,722
Xarelto Rivaroxaban Brand 312 $53,948
Mirtazapine Generic 2,471 $34,436
Atorvastatin Calcium Generic 3,392 $31,634
Descovy Emtricitabine/Tenofov Alafenam Brand 12 $29,498
Prezcobix Darunavir/Cobicistat Brand 11 $29,024

The 10 drugs with the highest cost, of 335 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$342,866

Medicare's payments for the services billed

Medicare patients

1,628

Average age 84

Services billed

3,163

1,070 women, 558 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Depression 55%
Alzheimer's or dementia 53%
Chronic kidney disease 47%
Ischemic heart disease 42%
Heart failure 40%
Atrial fibrillation 40%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record